To receive daily emails from Breaking Christian News to your inbox CLICK HERE

"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us." -Dr. John Farley

Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

The findings, published in the Feb. 14 edition of The Lancet Oncology, show that selumetinib targets a mutation in the MAPK pathway for patients with low-grade serous carcinoma, allowing for treatment on previously chemoresistant tumors.

"This is a potentially important breakthrough for the Gynecologic Oncology Group," said John Farley, MD, a gynecologic oncologist in the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology at the Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a Dignity Health Member.

This study was initially developed in 2007, with 52 patients enrolled for the Phase II clinical trial between December 2007 and November 2009. Patients were given 50 milligrams of selumetinib orally twice daily. Of those participants, eight had a measurable decrease in tumor size, seven had partial responses and 34 patients saw their tumors stabilize. The findings suggest that inhibitors of the MAPK pathway warrant further investigation in patients with low-grade ovarian cancer.

"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us," Dr. Farley said. He added that Phase III of this trial is scheduled to begin in the next few weeks, with that trial to be the "definitive test" before the treatment becomes available to the general population.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Trump Grants Federal Workers Two Additional Christmas Holidays

America Fest 2025: Erika Kirk Endorses 'My Husband's Friend' JD Vance for President

Brent Bozell Confirmed as US Ambassador to South Africa

Jury Quickly Convicts Judge Who Helped Illegal Migrant Escape ICE

Feds Estimate Somali-Linked Fraud in Walz's Minnesota Could Top $9 Billion

Trump SUSPENDS 'Green Card Lottery' after Program Let Brown University–MIT Shooting Suspect Enter the US

Brown, MIT Shooter Found Dead for Days in NH Storage Unit; Motive Still a Mystery

House Passes Bill to Criminalize Transgender Mutilation of Children

November Inflation Falls to 2.7%, Lower than Expected: 'This Is Good News for Wall Street; It’s Good News for Main Street'

MOVIEGUIDE's Review of the New Animated Film: DAVID

Massachusetts Drops Controversial Gender Ideology Mandate for Licensing Foster Care Parents

Nearly 40% of Women Suffer Severe Grief for Years after Abortion, Miscarriage: Study

Former Pfizer Vice President: COVID Shots Were 'Designed to Cause Injury,' Reduce Fertility

Dutch Sheets Shares a Warning from the US National Counterterrorism Center

Venezuela: Trump's Pressure Campaign and Maduro's Fury

President Trump Charts Accomplishments and Previews Future Policies during His Primetime Address

Secretary Hegseth and Franklin Graham Preach Gospel at Pentagon Christmas Service: 'Jesus Took Our Shame'

'Unsafe, Needless, Irreversible': HHS Sec. Kennedy Takes Sweeping Action to Reverse Biden-Era Policies on So-Called 'Gender Affirming Care'

Hobby Lobby Giving Away Half a Million Copies of Book Defending Biblical Christmas Story [Video]

Geothermal Blind Power Site Discovered in Nevada

Steve Shultz, Managing Editor
Founder and Owner

Aimee Herd, Editor